About Cyclin-dependent kinase 3
Cyclin-dependent kinase 3 (CDK3) is a protein
from Homo sapiens identified by UniProt accession
Q00526, 305 residues long.
MolForge cross-references it against 0 known binders and
42 disease associations.
Target properties
| Protein name | Cyclin-dependent kinase 3 |
|---|
| UniProt accession | Q00526 |
|---|
| Gene | CDK3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 305 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (3)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (42)
Diseases linked to this target (Open Targets).
- neoplasm · score 0.10
- lymphocyte count · score 0.10
- small cell lung carcinoma · score 0.08
- Mantle cell lymphoma · score 0.07
- chronic lymphocytic leukemia · score 0.07
- white matter hyperintensity measurement · score 0.05
- cancer · score 0.04
- non-small cell lung carcinoma · score 0.04
- lymphoma · score 0.04
- multiple myeloma · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q00526-F1 | alphafold | PREDICTED | 86.13 | — |
Amino-acid sequence (305 residues)
MDMFQKVEKI GEGTYGVVYK AKNRETGQLV ALKKIRLDLE MEGVPSTAIR EISLLKELKH PNIVRLLDVV HNERKLYLVF EFLSQDLKKY MDSTPGSELP LHLIKSYLFQ LLQGVSFCHS HRVIHRDLKP QNLLINELGA IKLADFGLAR AFGVPLRTYT HEVVTLWYRA PEILLGSKFY TTAVDIWSIG CIFAEMVTRK ALFPGDSEID QLFRIFRMLG TPSEDTWPGV TQLPDYKGSF PKWTRKGLEE IVPNLEPEGR DLLMQLLQYD PSQRITAKTA LAHPYFSSPE PSPAARQYVL QRFRH
Explore Cyclin-dependent kinase 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets